Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.02, FiscalAI reports.
Neumora Therapeutics Stock Performance
NASDAQ NMRA opened at $0.43 on Monday. The stock has a 50-day simple moving average of $0.60 and a 200 day simple moving average of $1.70. The company has a market capitalization of $80.59 million, a PE ratio of -0.35 and a beta of 3.12. The company has a current ratio of 4.50, a quick ratio of 4.50 and a debt-to-equity ratio of 1.19. Neumora Therapeutics has a 12 month low of $0.32 and a 12 month high of $3.65.
Insider Activity at Neumora Therapeutics
In other Neumora Therapeutics news, insider Daljit Singh Aurora sold 21,055 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $1.60, for a total value of $33,688.00. Following the sale, the insider directly owned 48,750 shares in the company, valued at approximately $78,000. This trade represents a 30.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last three months, insiders sold 307,127 shares of company stock valued at $481,160. Corporate insiders own 26.94% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms recently issued reports on NMRA. Wall Street Zen raised shares of Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, November 7th. Weiss Ratings raised shares of Neumora Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, September 25th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Neumora Therapeutics in a research note on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $6.57.
Check Out Our Latest Research Report on Neumora Therapeutics
Neumora Therapeutics Company Profile
Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases. Founded in 2020 and headquartered in Watertown, Massachusetts, the company researches potential medicines for conditions including depression, schizophrenia and agitation associated with Alzheimer’s disease. The company combines neuroscience research with data science and other computational approaches to identify disease targets and develop drug candidates. Its pipeline includes investigational medicines designed to act on specific biological pathways involved in brain disorders; these products are under development and are not approved treatments.
Featured Stories
- Five stocks we like better than Neumora Therapeutics
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
